BRIEF-Revive Therapeutics announces US FDA acceptance

Wed Jul 6, 2016 8:36am EDT
 
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

July 6 (Reuters) - Revive Therapeutics Ltd :

* Revive Therapeutics Ltd announces US FDA acceptance of IND of Bucillamine for the treatment of cystinuria

* Says "look forward to initiating this phase 2 study shortly" Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)